AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

ASX:PAAPharmaust Stock Price, Forecast & News

A$0.10
-0.01 (-8.70 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.11
Now: A$0.11
A$0.12
50-Day Range
A$0.06
MA: A$0.10
A$0.11
52-Week Range
A$0.04
Now: A$0.11
A$0.18
Volume3.27 million shs
Average VolumeN/A
Market Capitalization$31.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PharmAust Limited operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries. The company is based in Bentley, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6161 7412

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.26 million
Cash FlowA$0.01 per share
Book ValueA$0.03 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$31.71 million
Next Earnings DateN/A
OptionableOptionable

Receive PAA News and Ratings via Email

Sign-up to receive the latest news and ratings for PAA and its competitors with MarketBeat's FREE daily newsletter.

Pharmaust (ASX:PAA) Frequently Asked Questions

How has Pharmaust's stock been impacted by COVID-19 (Coronavirus)?

Pharmaust's stock was trading at A$0.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PAA stock has increased by 32.9% and is now trading at A$0.11. View which stocks have been most impacted by Coronavirus.

Has Pharmaust been receiving favorable news coverage?

News articles about PAA stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pharmaust earned a coverage optimism score of -3.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutPharmaust.

Who are some of Pharmaust's key competitors?

Who are Pharmaust's key executives?

Pharmaust's management team includes the following people:
  • Dr. Roger Aston B.Sc., BSc (Hons), Ph.D., Exec. Chairman & Acting CEO (Age 63)
  • Dr. Richard Mollard, Chief Scientific Officer
  • Mr. Robert Charles Bishop, Exec. Director
  • Mr. Sam Michael Wright A.C.I.S., M.A.I.C.D., AFin, DipAcc, ACIS, MAICD, Non-Exec. Director & Company Sec. (Age 41)
  • Dr. Martine Keenan, Chief Exec. Officer of Epichem Pty Ltd

What is Pharmaust's stock symbol?

Pharmaust trades on the ASX under the ticker symbol "PAA."

What is Pharmaust's stock price today?

One share of PAA stock can currently be purchased for approximately A$0.11.

How big of a company is Pharmaust?

Pharmaust has a market capitalization of $31.71 million and generates $4.26 million in revenue each year.

What is Pharmaust's official website?

The official website for Pharmaust is www.pharmaust.com.

How can I contact Pharmaust?

The company can be reached via phone at 61 8 6161 7412.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.